Critical care management of systemic mastocytosis: when every wasp is a killer bee
Hinke Y van der Weide1, David J van Westerloo2, Walter M van den Bergh1
1Department of Critical Care, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands. w.m.van.den.bergh@umcg.nl.
Abstract:
Since the critical care physician will most likely be involved in a life-threatening expression of systemic mastocytosis, recognition of this disease is of utmost importance in the critical care management of these patients. Mastocytosis is a severely under-recognized disease because it typically occurs secondary to another condition and thus may occur more frequently than assumed. In this article, we will review the current knowledge on the treatment of mastocytosis crises with an emphasis on critical care management. Mastocytosis is characterized by the clonal proliferation and accumulation of mast cells in different tissues. Mast cell mediators contain a wide range of biologically active substances that may lead to itching and hives but may ultimately lead to anaphylactic shock caused by the release of histamine and other mediators from mast cells. The mainstay of therapy is the avoidance of potential triggers of mast cell degranulation and, if unsuccessful, blocking the cascade of mast cell mediators. The critical care physician should be well aware of the special precautions which should be kept in mind throughout the management of a mastocytosis crisis to avoid massive mast cell degranulation. Histamine-releasing drugs and certain physical triggers like temperature change should be avoided.
Insights
Systemic mastocytosis requires critical care recognition due to potential life-threatening anaphylaxis. Prompt management involves avoiding mast cell degranulation triggers and blocking mediator release for patient safety.
Area of Science:
- Critical Care Medicine
- Hematology
- Immunology
Background:
- Mastocytosis is an under-recognized condition involving mast cell proliferation.
- Mast cell mediators can cause severe reactions, including anaphylactic shock.
- Critical care physicians often manage life-threatening mastocytosis crises.
Purpose of the Study:
- To review current knowledge on mastocytosis crisis treatment.
- To emphasize critical care management strategies for mastocytosis.
- To highlight precautions for avoiding mast cell degranulation.
Main Methods:
- Review of current literature on mastocytosis treatment and critical care.
- Emphasis on identifying and avoiding triggers of mast cell degranulation.
- Discussion of therapeutic strategies for mast cell mediator blockade.
Main Results:
- Mastocytosis crises can lead to anaphylaxis due to mediator release.
- Avoiding triggers like histamine-releasing drugs and physical stimuli is crucial.
- Management requires awareness of special precautions to prevent massive mast cell degranulation.
Conclusions:
- Early recognition of systemic mastocytosis is vital for critical care.
- Effective management hinges on avoiding triggers and blocking mediator cascades.
- Critical care physicians must be vigilant to prevent severe mast cell degranulation events.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Cystic Fibrosis: Management
Sinus disease and chronic...
Asthma-IV: Nursing Management
First, in...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Acute Coronary Syndrome IV: Interprofessional Care

